COSM

Cosmos Health ($COSM) CEO Continues Multi-Million Dollar Stock Buying as Company Hits Record Revenue

11/24/2025 19:57

Grigorios Siokas, CEO of Cosmos Health ($COSM), has been aggressively purchasing company shares from December 2024 through November 2025. Notably, he continued buying even when the stock fell to $0.32 in April and resumed purchases in November at $0.62-$0.68 per share. His total investment amounts to several million dollars, representing an unusually aggressive insider buying signal for a small-cap CEO. Cosmos Health is a Chicago-based healthcare company specializing in pharmaceutical distribution and nutraceutical manufacturing. Starting from European markets like Greece and Croatia, the company has recently expanded into the U.S. and GCC countries. Key revenue drivers include Sky Premium Life nutraceuticals and C-Sept disinfectant products, while Cana Laboratories provides European GMP-certified contract manufacturing services. The CEO's persistent buying coincides with notable operational improvements. Q3 2025 revenue surged 38% year-over-year to $17.11 million, marking the highest quarterly revenue in company history. More importantly, gross margins expanded from 9.72% to 15.21%, demonstrating improved operational efficiency. Adjusted EBITDA loss improved by 74%, confirming the profitability improvement trend. However, investors must carefully consider significant risk factors. The company still reports GAAP quarterly net losses of $5.35 million, with a debt-to-equity ratio of 91%, indicating high financial leverage. Cash reserves of only $922,000 raise liquidity concerns given ongoing operational cash burn. Despite these financial constraints, the company secured a $300 million digital financing facility, using funds to invest in digital assets like Ethereum while pursuing business expansion. Recent initiatives include U.S. market entry through FDA-certified manufacturing facilities and exclusive distribution rights in Oman, potentially serving as long-term growth catalysts. The stock chart shows recovery signs after a prolonged decline following the June-July 2024 surge. The $0.32-$0.86 range where the CEO concentrated his purchases now serves as support, suggesting insider conviction is reflected in price action. Key metrics investors should monitor include next quarter's revenue growth sustainability and potential adjusted EBITDA breakeven. Achievement of the targeted $60 million annual revenue and margin improvement through contract manufacturing expansion will be critical variables. The impact of digital asset investments on financial stability also requires close observation. Currently trading at 0.31x sales, the stock appears undervalued versus industry peers. However, persistent losses and high leverage pose additional downside risks. Whether the CEO's massive buying represents a bottom signal or mere support remains to be determined through the next 2-3 quarters' results.